Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study

著者: Elizabeth R. Plimack, Thomas Powles, V.P. Stus, Rustem Gafanov, Dmitry Nosov, Tom Waddell, B. Yа. Alekseev, Frédéric Pouliot, Bohuslav Melichar, Denis Soulières, Delphine Borchiellini, Raymond S. McDermott, Ihor Vynnychenko, Yen‐Hwa Chang, Satoshi Tamada, Michael B. Atkins, Chenxiang Li, Rodolfo F. Perini, L. Rhoda Molife, Jens Bedke, Brian I. Rini - European Urology 2023 被引用: 137